CHF2.07
1.67% today
SIX Swiss Exchange, Jun 12, 12:04 pm CET
ISIN
CH0363463438
Symbol
IDIA
Sector
Industry

Idorsia Stock price

CHF2.10
+0.79 60.31% 1M
+0.59 39.44% 6M
+1.28 155.47% YTD
-0.05 2.51% 1Y
-25.46 92.38% 5Y
-11.55 84.62% 10Y
-11.55 84.62% 20Y
SIX Swiss Exchange, Closing price Wed, Jun 11 2025
+0.08 3.70%
ISIN
CH0363463438
Symbol
IDIA
Sector
Industry

Key metrics

Market capitalization CHF455.23m
Enterprise Value CHF1.55b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 9.61
P/S ratio (TTM) P/S ratio 2.82
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 14.08%
Revenue (TTM) Revenue CHF161.33m
EBIT (operating result TTM) EBIT CHF-265.78m
Free Cash Flow (TTM) Free Cash Flow CHF-330.01m
Cash position CHF64.85m
EPS (TTM) EPS CHF-0.85
P/E forward negative
P/S forward 2.98
EV/Sales forward 10.15
Show more

Is Idorsia a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Idorsia Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Idorsia forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a Idorsia forecast:

Hold
100%

Financial data from Idorsia

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
161 161
14% 14%
100%
- Direct Costs 35 35
254% 254%
22%
127 127
4% 4%
78%
- Selling and Administrative Expenses 250 250
24% 24%
155%
- Research and Development Expense 124 124
44% 44%
77%
-239 -239
42% 42%
-148%
- Depreciation and Amortization 26 26
15% 15%
16%
EBIT (Operating Income) EBIT -266 -266
39% 39%
-165%
Net Profit -231 -231
312% 312%
-143%

In millions CHF.

Don't miss a Thing! We will send you all news about Idorsia directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The firm targets patients who are suffering with Fabry disease, insomnia, Cerebral vasospasm associated with aSAH and systemic lupus erythematosus. The was founded on March 3, 2017 and is headquartered in Allschwil, Switzerland.

Head office Switzerland
CEO André Muller
Employees 650
Founded 2017
Website www.idorsia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today